


## JNJ-26146900

Cat. No.:	HY-123310
CAS No.:	868691-50-3
Molecular Formula:	C <sub>15</sub> H <sub>15</sub> F <sub>3</sub> N <sub>2</sub> O <sub>3</sub> S
Molecular Weight:	360.35
Target:	Androgen Receptor
Pathway:	Vitamin D Related/Nuclear Receptor
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	JNJ-26146900 is a potent and orally active androgen receptor antagonist with a K <sub>i</sub> value of 400nM for rat AR. JNJ-26146900 is a nonsteroidal androgen receptor (AR) ligand. JNJ-26146900 reduces prostate tumor size and prevents bone loss. JNJ-26146900 can be used in research of cancer <sup>[1]</sup> .																
<b>In Vitro</b>	JNJ-26146900 bound to the rat androgen receptor transfected into Cos-7 cells with submicromolar potency <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.																
<b>In Vivo</b>	<p>JNJ-26146900 (10-100 mg/kg; p.o.; mature male Sprague-Dawley rats) reduces the wet weights of both the ventral prostate and levator ani muscle as effectively<sup>[1]</sup>.</p> <p>JNJ-26146900 (30-100 mg/kg; p.o.) prevents prostate tumor growth in the Dunning rat model, maximally inhibiting growth at a dose of 10mg/kg. JNJ-26146900 inhibits tumor growth significantly in a CWR22-LD1 mouse xenograft model of human prostate cancer<sup>[1]</sup>.</p> <p>JNJ-26146900 (30 mg/kg; p.o.; mature male Sprague-Dawley rats) reduces castration-induced tibial bone loss<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>mature male Sprague-Dawley rats<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10, 30, 100 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>oral gavage; daily, for 6 weeks</td> </tr> <tr> <td>Result:</td> <td>Reduced ventral prostate weight.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>CWR22-LD1 mouse xenograft model<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>30, 100 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>oral gavage; twice per day for 3 weeks</td> </tr> <tr> <td>Result:</td> <td>Inhibited tumor growth at 100 mg/kg, reducing mean tumor weight at Day 21 to about 30% of the intact vehicle tumor weight.</td> </tr> </table>	Animal Model:	mature male Sprague-Dawley rats <sup>[1]</sup>	Dosage:	10, 30, 100 mg/kg	Administration:	oral gavage; daily, for 6 weeks	Result:	Reduced ventral prostate weight.	Animal Model:	CWR22-LD1 mouse xenograft model <sup>[1]</sup>	Dosage:	30, 100 mg/kg	Administration:	oral gavage; twice per day for 3 weeks	Result:	Inhibited tumor growth at 100 mg/kg, reducing mean tumor weight at Day 21 to about 30% of the intact vehicle tumor weight.
Animal Model:	mature male Sprague-Dawley rats <sup>[1]</sup>																
Dosage:	10, 30, 100 mg/kg																
Administration:	oral gavage; daily, for 6 weeks																
Result:	Reduced ventral prostate weight.																
Animal Model:	CWR22-LD1 mouse xenograft model <sup>[1]</sup>																
Dosage:	30, 100 mg/kg																
Administration:	oral gavage; twice per day for 3 weeks																
Result:	Inhibited tumor growth at 100 mg/kg, reducing mean tumor weight at Day 21 to about 30% of the intact vehicle tumor weight.																

---

## REFERENCES

---

[1]. Lanter J, et, al. A selective androgen receptor modulator that reduces prostate tumor size and prevents orchidectomy-induced bone loss in rats. J Steroid Biochem Mol Biol. 2007 Jan;103(1):76-83.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA